Clinical Trials on Rectosigmoid Adenocarcinoma

Total 9452 results

University of Michigan Rogel Cancer Center

Withdrawn

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Metastatic Pancreatic Adenocarcinoma

United States
Veru Inc.

Terminated

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer (VERU-100)

Advanced Prostate Adenocarcinoma

United States
HonorHealth Research Institute
Celgene

Active, not recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
University Hospital, Montpellier
AIDS Malignancy Consortium

Active, not recruiting

Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) (DIPLOMA)

Pancreatic Ductal Adenocarcinoma

France
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Patrick Joseph Loehrer Sr.
Exelixis

Terminated

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Metastatic

United States
Clovis Oncology, Inc.

Completed

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma

United States
Bagcilar Training and Research Hospital

Completed

Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy

Adenocarcinoma of Prostate

Turkey
Oncolytics Biotech
University of Texas

Completed

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma

United States
Royal Marsden NHS Foundation Trust

Completed

Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma

Adenocarcinoma of Oesophagus

United Kingdom
National Cancer Institute, Naples

Recruiting

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Adenocarcinoma of the Pancreas

Italy, Spain
Georgetown University
Merck Sharp & Dohme LLC; BioXcel Therapeutics Inc

Recruiting

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Peking University People's Hospital

Not yet recruiting

Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma (NICLA)

Adenocarcinoma of Esophagogastric Junction

China
West Virginia University

Recruiting

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas

United States
Cedars-Sinai Medical Center

Recruiting

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC - Pancreatic Ductal Adenocarcinoma

United States
National University Hospital, Singapore

Recruiting

A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Metastatic Pancreatic Ductal Adenocarcinoma

Singapore
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Metastatic Pancreatic Ductal Adenocarcinoma

United States, China, Hungary, Taiwan, Belgium, Germany, Spain, Italy, Czechia, France, Japan, Switzerland, Australia, Israel, Korea, Republic of, Canada, Russian Federation, Slovakia, United Kingdom, Turkey, Sweden, Greece, Finland, ... and more
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Centre Georges Francois Leclerc

Active, not recruiting

Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma (STEREO-RML)

Adenocarcinoma of the Prostate

France
Qilu Hospital of Shandong University

Completed

Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients

Pancreatic Ductal Adenocarcinoma (PDAC)

China
Threshold Pharmaceuticals
PRA Health Sciences

Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Cambridge University Hospitals NHS Foundation Trust

Terminated

Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma

Adenocarcinoma of the Stomach

United Kingdom
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)

China
Azienda Ospedaliera Universitaria Integrata Verona

Recruiting

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability (CASPER)

PDAC - Pancreatic Ductal Adenocarcinoma

Italy
Shanghai Zhongshan Hospital

Recruiting

A Prospective Observation Registry Study on the Alimentary Reconstruction After Radical Proximal Gastrectomy (STAR-PG01)

Reconstruction | Proximal Gastric Adenocarcinoma

China
Xijing Hospital

Recruiting

Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
OBI Pharma, Inc

Terminated

A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Pancreatic Adenocarcinoma | Solid Tumor

United States
Candel Therapeutics, Inc.
Mayo Clinic

Active, not recruiting

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02)

Borderline Resectable Pancreatic Adenocarcinoma

United States, Mexico
Baptist Health South Florida
AstraZeneca

Terminated

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas

United States
Sierra Oncology LLC - a GSK company

Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Centre Hospitalier Universitaire de Nīmes

Active, not recruiting

EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients

Adenocarcinoma of the Prostate

France
Pfizer
Celgene

Completed

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Metastatic Pancreatic Ductal Adenocarcinoma

United States, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

Adenocarcinoma of the Prostate

United States
Jules Bordet Institute

Completed

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) (RegARd-C)

Advanced Chemorefractory Colorectal Adenocarcinoma

Belgium
James Taylor

Completed

The Prostate Immobilization Device Study

Adenocarcinoma of the Prostate

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer

Metastatic Adenocarcinoma | Advanced Adenocarcinoma

United States
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors (MATILDA)

Metastatic Colorectal Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Prostate Adenocarcinoma | Stomach Adenocarcinoma
Eisai Inc.

Completed

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

KIF5B-RET-Positive Adenocarcinoma of the Lung

United States, Hong Kong, Japan, Taiwan, Singapore
Marina Garassino

Recruiting

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)

Advanced LKB1-inactive Lung Adenocarcinoma

Italy
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

China
National OncoVenture
Hanmi Pharmaceutical Company Limited

Terminated

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Adenocarcinoma of Lung Stage IV | Adenocarcinoma of Lung Stage IIIB

Korea, Republic of
AIO-Studien-gGmbH

Completed

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NintNivo)

Adenocarcinoma of the Lung

Germany
Seagen Inc.

Active, not recruiting

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Korean Association for the Study of Targeted Therapy
Chonnam National University Hospital; Kyungpook National University Hospital; Konkuk University Medical Center and other collaborators

Completed

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

HER2 Gene Mutation | Adenocarcinoma Lung Stage IV

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Vanderbilt-Ingram Cancer Center
AstraZeneca; Syndax Pharmaceuticals

Terminated

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Primary Peritoneal... and other conditions

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Active, not recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States

Clinical Trials on Rectosigmoid Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations